||Eriodictyol has vasodilator, anti-inflammatory and antioxidant activities, it is an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor.
Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance, it attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats. It may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis. |
||COX | TLR | gp120/CD4 | p38MAPK | ERK | JNK | ROS | IL Receptor | PPAR | PI3K | Akt | TNF-α | VEGFR | NOS | TRPV | EGFR | MEK | ERK|
|BMB Rep. 2013 Dec;46(12):594-9. |
|Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway.[Pubmed: 24195792]|
|The anti-inflammatory activity of Eriodictyol and its mode of action were investigated.
METHODS AND RESULTS:
Eriodictyol suppressed tumor necrosis factor (mTNF)-α, inducible nitric oxide synthase (miNOS), interleukin (mIL)-6, macrophage inflammatory protein (mMIP)-1, and mMIP-2 cytokine release in LPS-stimulated macrophages. We found that the anti-inflammatory cascade of Eriodictyol is mediated through the Toll-like Receptor (TLR)4/CD14, p38 mitogen-activated protein kinases (MAPK), extracellular-signal-regulated kinase (ERK), Jun-N terminal kinase (JNK), and cyclooxygenase (COX)-2 pathway. Fluorescence quenching and saturation-transfer difference (STD) NMR experiments showed that Eriodictyol exhibits good binding affinity to JNK, 8.79 × 10(5) M(-1). Based on a docking study, we propose a model of Eriodictyol and JNK binding, in which Eriodictyol forms 3 hydrogen bonds with the side chains of Lys55, Met111, and Asp169 in JNK, and in which the hydroxyl groups of the B ring play key roles in binding interactions with JNK.
Therefore, Eriodictyol may be a potent anti-inflammatory inhibitor of JNK.
|Biol Pharm Bull. 2007 Jan;30(1):32-7. |
|The anti-apoptotic and anti-oxidant effect of eriodictyol on UV-induced apoptosis in keratinocytes.[Pubmed: 17202655]|
|Recently, considerable scientific and therapeutic interest has focused on the structure and functions of the flavonoids. In a previous study, we suggested that hydroxyl (OH) substitutions on specific carbons in the skeleton of the flavonoids might significantly affect their apoptosis-modulating properties.
METHODS AND RESULTS:
Here, to investigate the effect of various OH substitutions on their diphenylpropane (C6C3C6) skeleton carbons, we selected 10 different flavonoids and assessed their role on UV-induced apoptosis of human keratinocytes, the principal cell type of epidermis. The results showed that 5,7,3',4'-tetrahydroxylflavanone (Eriodictyol) and 3,4'-dihydroxy flavone (3,4'-DHF) had a positive effect on cell proliferation of human HaCaT keratinocytes. Treatment with Eriodictyol in particular resulted in significant suppression of cell death induced by ultraviolet (UV) light, a major skin-damaging agent. We found that Eriodictyol treatment apparently reduced the percentage of apoptotic cells and the cleavage of poly(ADP-ribose) polymerase, concomitant with the repression of caspase-3 activation and reactive oxygen species (ROS) generation. The anti-apoptotic and anti-oxidant effects of Eriodictyol were also confirmed in UV-induced cell death of normal human epidermal keratinocyte (NHEK) cells.
Taken together, these findings suggest that Eriodictyol can be used to protect keratinocytes from UV-induced damage, implying the presence of a complex structure-activity relationship (SAR) in the differential apoptosis-modulating activities of various flavonoids.
|Biol Pharm Bull. 2013;36(8):1375-9. |
|Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice.[Pubmed: 23902981]|
|Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that Eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase.
METHODS AND RESULTS:
In this study, we investigated the inhibitory effect of Eriodictyol on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in ICR mice. Treatment with 2 mg/mL Eriodictyol for DNCB-induced AD-like skin lesions in ICR mice improved scratching behavior and skin severity score. Histological analysis demonstrated that thickening of the skin lesions were significantly reduced in the Eriodictyol-treated group. Also, Eriodictyol suppressed the DNCB-mediated elevation of IgE serum levels.
These results suggest that Eriodictyol may be a potential therapeutic resource for AD and an adjunctive agent to control itchiness in AD.
|Biochem Pharmacol. 2012 Jul 1;84(1):88-92. |
|Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats.[Pubmed: 22484312 ]|
|Diabetic retinopathy is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis. We hypothesized that Eriodictyol, one of the most abundant dietary flavonoids, could be effective against diabetic retinopathy, which involves significant oxidative stress and inflammation.
METHODS AND RESULTS:
The aim of the present study was to investigate the effects of Eriodictyol in early retinal and plasma changes of streptozotocin-induced diabetic rats. The effect of Eriodictyol treatment (0.1, 1, 10 mg/kg daily for 10 days) was evaluated by TNF-α, ICAM-1, VEGF, and eNOS protein levels measurement in the retina, plasma lipid peroxidation, and blood-retinal barrier (BRB) integrity. Increased amounts of cytokines, adhesion molecule, and nitric oxide synthase were observed in retina from diabetic rats. Eriodictyol treatment significantly lowered retinal TNF-α, ICAM-1, VEGF, and eNOS in a dose-dependent manner. Further, treatment with Eriodictyol significantly suppressed diabetes-related lipid peroxidation, as well as the BRB breakdown.
These data demonstrated that Eriodictyol attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the BRB in early diabetic rats.